{"id":"W4283687131","doi":"10.1136/annrheumdis-2022-eular.1186","title":"POS1024 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 1","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Placebo; Adverse effect; Rheumatology; Clinical endpoint; Randomized controlled trial; Gastroenterology; Surgery; Arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001135722,0.0008053393,0.001668036,0.0002980826,0.0003866934,0.0008130369,0.0004469474,0.001122645,0.00492669],"category_scores_gemma":[0.0007947876,0.0004013926,0.001675847,0.0002157901,0.0005041804,0.0008640853,0.0002972545,0.002502337,0.00187184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005022903,"about_ca_system_score_gemma":0.000499612,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008878637,"about_ca_topic_score_gemma":0.001345974,"domain_scores_codex":[0.9995582,0.0001163027,0.00003840497,0.00008368825,0.00008729839,0.0001161012],"domain_scores_gemma":[0.9995111,0.0001105022,0.0001017782,0.00006607762,0.00004343001,0.0001671631],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6788978,0.02397278,0.0154034,0.0009234293,0.002070799,0.0004612851,0.0002341544,0.002377763,0.05881129,0.0002354615,0.00728163,0.2093303],"study_design_scores_gemma":[0.2375502,0.6301193,0.1088349,0.0001611679,0.002052782,0.0007861934,0.0001955115,0.001937315,0.01044276,0.0002870091,0.007507421,0.0001254139],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914255,0.003591939,0.0002301401,0.0004193188,0.0001567376,0.0002881202,0.001486705,0.00009184518,0.002309728],"genre_scores_gemma":[0.9883994,0.001612414,0.0004396458,0.0007972681,0.0001610613,0.0002067632,0.003033072,0.00003995375,0.005310461],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00492669,"threshold_uncertainty_score":0.0164814,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02236427850623391,"score_gpt":0.2571326608538491,"score_spread":0.2347683823476152,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}